Wasatch Advisors Inc Bio Atla, Inc. Transaction History

Wasatch Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $1.71 Million - $3.09 Million	-1,006,797 Reduced 67.08%	494,137 $840,000
Q2 2023 Aug 07, 2023	BUY	$2.83 - $3.87 $658,724 - $900,800	232,765 Added 18.35%	1,500,934 $4.5 Million
Q1 2023 May 12, 2023	BUY	$2.3 - $8.25 $1.59 Million - $5.69 Million	689,193 Added 119.04%	1,268,169 $3.4 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $3.64 Million - $6.37 Million	578,976 New	578,976 $4.78 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.